Trial Profile
Exploratory study for biomarkers to predict efficacy and toxicity to Sorafenib in patients with advanced hepatocellular carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2019
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
- 05 Sep 2019 Status changed from recruiting to completed.
- 07 Sep 2012 New trial record